The “WHO pain scale” most people encounter online is actually the WHO Analgesic Ladder, a three-step framework the World Health Organization published in 1986 to guide doctors in treating cancer pain. It is not a tool for measuring how much pain someone feels but rather a strategy for choosing the right medications based on pain severity. The ladder starts with basic painkillers for mild pain and escalates through weak opioids to strong opioids as pain worsens, with the option of adding supportive medications at every step. Though it was designed specifically for cancer, its influence has spread across nearly every area of medicine where pain management matters.
How the Three Steps Work
The WHO Analgesic Ladder organizes pain treatment into three tiers, each corresponding to a different level of pain intensity. The idea is straightforward: you start at the bottom and move up only when the current step no longer provides adequate relief.
- Step 1 (mild pain): Non-opioid painkillers such as paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs like ibuprofen. These are the foundation, and they can be combined with adjuvant medications if needed.
- Step 2 (mild-to-moderate pain): Weak opioids such as codeine or tramadol, typically combined with the non-opioid painkillers from Step 1. The goal is to add opioid relief without jumping straight to the most powerful drugs.
- Step 3 (moderate-to-severe pain): Strong opioids such as morphine, oxycodone, or fentanyl, again potentially combined with non-opioids and adjuvant drugs. The European Association for Palliative Care has recommended starting with immediate-release oral morphine given every four hours, with extra doses available for breakthrough pain.
At every step, so-called adjuvant medications can be added. These are drugs that are not painkillers in themselves but that improve pain control or address a specific type of pain. Antidepressants, anticonvulsants, and corticosteroids all fall into this category. In a study of over 800 patients with nerve-related cancer pain managed according to the WHO ladder, the most frequently used adjuvants were amitriptyline, gabapentin, and dexamethasone, often in combination. The study found that following WHO guidelines with these additions could relieve neuropathic cancer pain in the majority of patients.1PubMed. Management of neuropathic cancer pain following WHO analgesic ladder: a prospective study
Pain Assessment Tools Used Alongside the Ladder
The ladder itself does not measure pain. To decide which step a patient belongs on, clinicians rely on separate pain assessment instruments. The most common is the Numerical Rating Scale, where you rate your pain from 0 (no pain) to 10 (worst imaginable). There is also the Visual Analogue Scale, a line you mark to show pain intensity, and the Wong-Baker FACES scale, which uses cartoon faces ranging from smiling to crying and is widely used with children or patients who have difficulty with numbers.
These scales feed into the ladder. A score of 1 to 3 on a 0–10 scale generally maps to Step 1 treatment. Scores of 4 to 6 point toward Step 2. Anything above 6 or 7 typically calls for Step 3 medications. The connection between “the WHO pain scale” that people search for and the WHO Analgesic Ladder is this pairing: the rating tools generate a number, and the ladder tells the clinician what to do with it.
A study comparing the standard WHO ladder approach with a severity-based approach in emergency patients with acute abdominal pain found that satisfaction was somewhat higher when analgesics were chosen based directly on pain intensity scores rather than by climbing the ladder step by step, though the difference was not large enough to be statistically significant.2Apollo Medicine. Comparison of WHO Pain Ladder Management versus Severity-based Pain Management in Patients Presented with Acute Abdominal Pain Visiting Emergency Department This hints at a broader tension: the ladder was designed for cancer pain that gets worse over time, not for acute episodes where you might want to match treatment intensity to the score right away.
Does the Ladder Actually Work?
The evidence behind the WHO ladder is surprisingly messy. An early systematic review in JAMA examined the first eight studies claiming to evaluate the ladder’s effectiveness and found that none of them included a control group, making a formal meta-analysis impossible. Some were retrospective, others had high dropout rates or inconsistent follow-up periods. Still, across these flawed studies, adequate pain relief was reported in roughly 69% to 100% of patients.3JAMA. The WHO Analgesic Ladder for Cancer Pain Management: Stepping Up the Quality of Its Evaluation The authors concluded that while the data were encouraging, they were not strong enough to confidently confirm the ladder’s effectiveness.
A more recent integrative review spanning 25 studies published since 1987 found that the WHO guidelines could provide pain relief to between 20% and 100% of cancer patients, depending on their stage of treatment and how pain relief was defined.4PubMed Central. Effectiveness of the World Health Organization cancer pain relief guidelines: an integrative review That is an enormous range, and it reflects a real limitation: the ladder is a framework, not a protocol. How well it works depends on how it is applied, what drugs are available, and how aggressively clinicians assess and re-assess pain.
The wide variation in reported success also reflects differences in how studies defined “adequate” relief. Some counted any improvement as success, while others required pain scores to drop below a specific threshold. Without standardized outcome measures, comparing studies is like comparing recipes that each define “a pinch of salt” differently.
The Debate Over Step 2
One of the most contested parts of the ladder is whether Step 2 should exist at all. The weak opioids sitting on that middle rung, drugs like codeine and tramadol, have come under sustained criticism from multiple directions.
A commentary in the British Journal of Anaesthesia argued that the 1986 classification of opioids as either “weak” or “strong” has been both inadvertently and deliberately misused, contributing to real harm. The authors contended that the distinction is arbitrary because all opioids carry the potential for misuse and adverse effects, and calling some of them “weak” may give prescribers and patients a false sense of safety.5British Journal of Anaesthesia. Misappropriation of the 1986 WHO analgesic ladder: the pitfalls of labelling opioids as weak or strong
There is also a practical argument: codeine does not work the same way in everyone. It is a prodrug that must be converted into morphine by a liver enzyme, and genetic variation means some people convert almost none of it while others convert too much. Tramadol has a similar enzymatic dependency. The result is unpredictable pain relief at Step 2, which has led some researchers to ask whether skipping it entirely makes more sense.
An international randomized trial directly tested this question by comparing the standard three-step approach with a two-step approach that jumped from non-opioids straight to low-dose strong opioids. Among 153 cancer patients, there was no significant difference in the time to stable pain control between the two groups. Over half the patients who started on the traditional Step 2 ended up needing to switch to a strong opioid anyway, with a median time to that switch of just six days. Patients in the two-step group experienced less nausea and lower costs.6PubMed. An international, open-label, randomised trial comparing a two-step approach versus the standard three-step approach of the WHO analgesic ladder in patients with cancer An earlier study comparing the same two approaches had similarly found that skipping Step 2 could be at least as effective as the traditional route.7PubMed. A validation study of the WHO analgesic ladder: a two-step vs three-step strategy
This is not just an academic question. In many low- and middle-income countries, weak opioids like codeine are more expensive and harder to obtain than low doses of morphine. Eliminating Step 2 could simplify treatment and reduce costs in exactly the settings where the WHO ladder was originally meant to help the most.
Proposed Additions to the Ladder
When strong opioids at Step 3 are not enough or cause intolerable side effects, the original ladder offers no guidance on what comes next. This gap has prompted proposals for a fourth and even fifth step.
The most widely discussed fourth step involves interventional procedures: nerve blocks, intrathecal drug-delivery pumps, and spinal cord stimulation. These techniques can deliver pain relief directly to the nervous system, bypassing many of the systemic side effects of oral or transdermal opioids. One review noted that cancer pain can be controlled with several such interventions when standard opioids are inadequate, though a risk-to-benefit assessment should come first.8PubMed. Interventional treatment of cancer pain: the fourth step in the World Health Organization analgesic ladder? A persistent problem, however, is timing: referrals for these procedures often come too late to meaningfully improve quality of life.9PubMed. Interventional pain management in patients with cancer-related pain
A separate proposal outlined a five-step ladder that adds opioid switching as Step 4 and places interventional procedures at Step 5. The reasoning is that the original ladder focuses entirely on whether pain is relieved but ignores side effects. If a patient on morphine at Step 3 develops severe constipation, nausea, or sedation, simply increasing the dose is counterproductive. The proposed fourth step would switch the patient to a different strong opioid, since individuals often respond very differently to various opioids. In a prospective study by the authors, three of the four factors predicting the need to switch were opioid-induced side effects rather than inadequate pain relief.10European Journal of Pain Supplements. Proposed 5‐step World Health Organization analgesic and side effect ladder Only when switching opioids also fails would anaesthetic interventions be considered.
Pain Management in Children
The WHO itself updated its guidance for pediatric cancer pain to recommend a two-step rather than three-step approach. The rationale echoes the adult debate over Step 2: codeine metabolizes unpredictably in children, and its safety profile in younger patients has led several countries to restrict or ban its use in pediatric populations. Under the revised pediatric guidelines, clinicians move from non-opioid analgesics directly to low-dose strong opioids when basic pain relief is inadequate.11Anaesthesia, Pain & Intensive Care. Cancer pain in children: a two-step strategy
A quality-improvement study across eight German pediatric oncology centers prospectively documented in-patient pain treatment over about 18 months. On Step 2, tramadol was nearly the only weak opioid used, and interestingly, average daily pain scores were lower with tramadol alone than with tramadol combined with a non-opioid. On Step 3, morphine was part of the regimen on most treatment days and was combined with a non-opioid on about 41% of those days.12Elsevier / European Journal of Pain. Paediatric cancer pain management using the WHO analgesic ladder–results of a prospective analysis from 2265 treatment days during a quality improvement study The pediatric setting highlights a broader theme: the original three-step design has been gradually adapted as the evidence base catches up with clinical experience.
Using the Ladder Outside of Cancer
The WHO ladder was built for cancer pain that tends to worsen over time, but clinicians have applied it to a wide range of conditions: post-surgical pain, arthritis, lower back pain, sickle cell disease, and more. Whether the ladder makes sense in these settings is a genuinely open question.
A review specifically addressing chronic non-cancer pain argued that the original ladder is not appropriate for that population and proposed a revised four-step version. The key difference: integrative therapies like physical therapy, cognitive behavioral therapy, and acupuncture would be incorporated at every step, and interventional procedures would come before strong opioids rather than after them. The rationale is that chronic non-cancer pain usually does not follow the linear worsening trajectory of cancer pain, and the risks of long-term opioid use, including dependence, are higher when the underlying condition is not terminal.13PubMed Central. The Modified WHO Analgesic Ladder: Is It Appropriate for Chronic Non-Cancer Pain?
This modified version essentially flips the logic of the upper steps. In cancer care, you try opioids before interventional procedures because the priority is rapid relief and quality of remaining life. In chronic non-cancer pain, you try interventional approaches first because you are managing a condition the patient may live with for decades, and long-term opioid use carries its own burden.
Global Access and the Opioid Paradox
The WHO designed the analgesic ladder partly as a response to the widespread under-treatment of cancer pain in developing countries. Decades later, access to the medications the ladder recommends remains deeply uneven. A survey of opioid availability across the Middle East found that, with one exception, opioid access remained low throughout the region. Several countries had severe formulary deficiencies, and even when opioids appeared on paper, they were often physically unavailable. Widespread over-regulation further impaired access.14PubMed. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in the Middle East: a report from the Global Opioid Policy Initiative (GOPI)
This creates a painful irony. In parts of the world where cancer pain treatment is most needed, the medications required for Steps 2 and 3 of the ladder simply do not exist in practice. Meanwhile, in high-income countries, the widespread availability of opioids has contributed to a different crisis: addiction, overdose, and death. The same ladder that cannot be implemented in one setting has been blamed for enabling over-prescribing in another. This dual reality has shaped much of the contemporary critique of the WHO framework and explains why many of the proposed modifications focus on reducing or delaying opioid use rather than simply climbing the original steps.
How Pain Affects Daily Life
Understanding why the ladder matters requires appreciating what uncontrolled cancer pain actually does to a person’s life. A cross-sectional study of cancer patients in Malaysia found that pain affected sleep in about 88% of patients, impaired normal physical activity in roughly 93%, and decreased appetite in nearly 79%. Emotional well-being was disrupted in about 72% of patients, and personal relationships were affected in about 36%.15PubMed Central. The Characteristics and the Pharmacological Management of Cancer Pain and Its Effect on the Patients’ Daily Activities and their Quality of Life: A Cross – Sectional study from Malaysia These numbers put the pharmacological debates in context. Whether the ladder has three steps or two, whether Step 2 is retained or discarded, the underlying urgency is the same: unmanaged pain does not just hurt, it dismantles the ability to function as a person.
This is also why pain assessment tools matter so much as companions to the ladder. A patient who reports a 7 out of 10 on a numerical scale is communicating not just a sensation but a cascade of functional losses. The number is a shorthand for disrupted sleep, lost appetite, strained relationships, and emotional distress. Effective use of the WHO ladder means treating all of that, not just chasing a lower score.
Opioid Switching and Side-Effect Management
One area the original 1986 ladder largely ignored is what happens when the right drug at the right step causes unbearable side effects. Constipation, drowsiness, nausea, and confusion are common with opioids, and for some patients these problems are as disabling as the pain itself. The original framework essentially said: if pain persists, move up a step. It did not say what to do when the current step controls pain but makes the patient miserable in other ways.
Opioid switching, sometimes called opioid rotation, is the practice of replacing one opioid with a different one at an equivalent analgesic dose. People metabolize different opioids through different pathways, so a patient who gets severe nausea from morphine may tolerate oxycodone or hydromorphone just fine. The five-step ladder proposal discussed earlier formalized this concept as its own dedicated step, recognizing that side effects, not just pain, should trigger a change in management. Clinical experience broadly supports this: switching opioids can restore a tolerable balance between pain relief and quality of life without requiring more aggressive interventions.
The Ladder as a Communication Tool
Whatever its clinical limitations, the WHO Analgesic Ladder has served an important role as a shared language. Before 1986, pain management in many parts of the world was haphazard. There was no widely agreed-upon framework that a nurse in rural sub-Saharan Africa and an oncologist in a European teaching hospital could both reference. The ladder gave everyone the same mental model: assess pain, start simple, escalate rationally, and add adjuvant drugs as needed.
That simplicity is both its greatest strength and its most cited weakness. A three-step framework is easy to teach, easy to remember, and easy to implement with minimal resources. It translates well across languages and medical traditions. But pain itself is not simple. Neuropathic pain does not respond to the same drugs as inflammatory pain. A patient with bone metastases has a different pain profile than a patient with pancreatic cancer compressing a nerve plexus. The ladder provides a starting point, not a personalized treatment plan, and the decades of modifications and critiques are really about acknowledging that starting point and building something more sophisticated around it.